HomeCompareCSGKF vs JNJ

CSGKF vs JNJ: Dividend Comparison 2026

CSGKF yields 6.74% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSGKF wins by $957.00 in total portfolio value
10 years
CSGKF
CSGKF
● Live price
6.74%
Share price
$0.89
Annual div
$0.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$1,034.85
Full CSGKF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CSGKF vs JNJ

📍 CSGKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSGKFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSGKF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSGKF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSGKF
Annual income on $10K today (after 15% tax)
$573.03/yr
After 10yr DRIP, annual income (after tax)
$879.62/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,106.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSGKF + JNJ for your $10,000?

CSGKF: 50%JNJ: 50%
100% JNJ50/50100% CSGKF
Portfolio after 10yr
$30.8K
Annual income
$2,862.13/yr
Blended yield
9.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CSGKF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSGKF buys
0
JNJ buys
0
No recent congressional trades found for CSGKF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSGKFJNJ
Forward yield6.74%2.13%
Annual dividend / share$0.06$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$31.2K$30.3K
Annual income after 10y$1,034.85$4,689.40
Total dividends collected$8.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSGKF vs JNJ ($10,000, DRIP)

YearCSGKF PortfolioCSGKF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,374$674.16$10,592$272.30+$782.00CSGKF
2$12,887$716.63$11,289$357.73+$1.6KCSGKF
3$14,548$758.83$12,123$472.89+$2.4KCSGKF
4$16,367$800.59$13,141$629.86+$3.2KCSGKF
5$18,354$841.77$14,408$846.81+$3.9KCSGKF
6$20,521$882.23$16,021$1,151.60+$4.5KCSGKF
7$22,880$921.86$18,122$1,588.22+$4.8KCSGKF
8$25,442$960.56$20,930$2,228.20+$4.5KCSGKF
9$28,221$998.25$24,792$3,191.91+$3.4KCSGKF
10$31,231$1,034.85$30,274$4,689.40+$957.00CSGKF

CSGKF vs JNJ: Complete Analysis 2026

CSGKFStock

Credit Suisse Group AG, together with its subsidiaries, provides various financial services in Switzerland, Europe, the Middle East, Africa, the Americas, and Asia Pacific. The company offers wealth management solutions, including investment advice and discretionary asset management services; risk management solutions, such as managed investment products; and wealth planning, succession planning, and trust services. It also provides financing and lending solutions, including consumer credit and real estate mortgage lending, real asset lending relating to ship, and aviation financing for UHNWI; standard and structured hedging, and lombard lending solutions, as well as collateral trading services; and investment banking solutions, such as global securities sales, trading and execution, capital raising, and advisory services. In addition, the company offers banking solutions, such as payments, accounts, debit and credit cards, and product bundles; asset management products; equity and debt underwriting, and advisory services; cash equities, equity derivatives, and convertibles, as well as prime services; and fixed income products, such as credit, securitized, macro, emerging markets, financing, structured credit, and other products. Further, it provides HOLT, a framework for assessing the performance of approximately 20,000 companies; and equity and fixed income research services. The company serves private and institutional clients; ultra-high-net-worth individuals, high-net-worth individuals, and affluent and retail clients; corporate clients, small and medium-sized enterprises, external asset managers, financial institutions, and commodity traders; and pension funds, hedge funds, governments, foundations and endowments, corporations, entrepreneurs, private individuals, financial sponsors, and sovereign clients. As of December 31, 2021, it operated through a network of 311 offices and branches. The company was founded in 1856 and is based in Zurich, Switzerland.

Full CSGKF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CSGKF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSGKF vs SCHDCSGKF vs JEPICSGKF vs OCSGKF vs KOCSGKF vs MAINCSGKF vs ABBVCSGKF vs MRKCSGKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.